<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802577</url>
  </required_header>
  <id_info>
    <org_study_id>2011-KAEK-25 2020/12-10</org_study_id>
    <nct_id>NCT04802577</nct_id>
  </id_info>
  <brief_title>Fatigue in Primary Sjögren's Syndrome</brief_title>
  <official_title>The Level of Fatigue and Its Relationship With Disease Activity, Pain, Insomnia, and Psychometric Parameters in Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bursa Yüksek İhtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bursa Yüksek İhtisas Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatigue is a common clinical finding in Primary Sjögren's syndrome (PSS). In PSS, there is&#xD;
      not enough data about the conditions in which fatigue develops and which clinical conditions&#xD;
      the disease is associated with. This study was aimed to determine the level of fatigue in&#xD;
      Primary Sjögren syndrome and to investigate the factors affecting the level of fatigue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While fatigue is seen with a prevalence of 7-8% in the normal population, it is more&#xD;
      prevalent in Primary Sjögren's syndrome (PSS). In the studies conducted so far, the frequency&#xD;
      of fatigue was seen at a frequency of over 30% in Primary Sjögren's syndrome. Although&#xD;
      fatigue is so common in PSS, there is not enough data about the conditions in which fatigue&#xD;
      develops in PSS. Other common conditions in PSS, apart from fatigue, are psychometric&#xD;
      disorders such as common pain, depression and anxiety, and sleep disorders. In the studies&#xD;
      conducted so far, each situation mentioned is common in PSS and seems to be related to each&#xD;
      other. In the literature, there is no data on how many psychometric parameters, pain level,&#xD;
      and insomnia affect fatigue and which are independent risk factors in PSS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>FACIT-F</measure>
    <time_frame>1 day</time_frame>
    <description>FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATİQUE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BDI</measure>
    <time_frame>1 day</time_frame>
    <description>Beck Depression Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAI</measure>
    <time_frame>1 day</time_frame>
    <description>Beck Anxiety Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISS</measure>
    <time_frame>1 day</time_frame>
    <description>Insomnia Severity Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDQ</measure>
    <time_frame>1 day</time_frame>
    <description>Pain Detect Questionnaire</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <condition>Fatigue</condition>
  <condition>Pain Syndrome</condition>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Primary Sjögren's syndrome</arm_group_label>
    <description>The patient's diagnosed with Primary Sjögren's according to 2016 ACR/EULAR classification criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy hospital workers without any chronic disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FACT-F questionnaire</intervention_name>
    <description>The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Primary Sjögren's syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Beck Depression Inventory</intervention_name>
    <description>The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Primary Sjögren's syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Beck Anxiety Inventory</intervention_name>
    <description>The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Primary Sjögren's syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Insomnia severity index.</intervention_name>
    <description>The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Primary Sjögren's syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ESSPRI</intervention_name>
    <description>The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.</description>
    <arm_group_label>Primary Sjögren's syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ESSDAI</intervention_name>
    <description>Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.</description>
    <arm_group_label>Primary Sjögren's syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pain Detect Questionnaire</intervention_name>
    <description>The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Primary Sjögren's syndrome</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Erythrocyte sedimentation rate, CRP, routine biochemical tests, and hemogram&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteers who were followed up with a diagnosis of PSS in the center where the study was&#xD;
        conducted and met the inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with PSS according to the 2016 ACR / EULAR criteria&#xD;
&#xD;
          -  Healthy hospital staff&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Cancer patients&#xD;
&#xD;
          -  Those with other connective tissue diseases other than PSS&#xD;
&#xD;
          -  Multiple sclerosis patients&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Those with heart failure and adrenal insufficiency&#xD;
&#xD;
          -  Those with renal failure: GFR &lt;60 ml/min&#xD;
&#xD;
          -  Anemia: Hemoglobin &lt;11 g / dl in women, hemoglobin &lt;12 g / dl in men&#xD;
&#xD;
          -  Hypothyroidism: TSH &gt;5 mu / L&#xD;
&#xD;
          -  Those with electrolyte disturbance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Koray Ayar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univesity of Health Science, Bursa Yuksek Ihtisas Training and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koray Ayar, M.D.</last_name>
    <phone>+902242955000</phone>
    <email>ayarkoray@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Koray Ayar</name>
      <address>
        <city>Yıldırım</city>
        <state>Bursa</state>
        <zip>16310</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koray Ayar, M.D.</last_name>
      <phone>02242955000</phone>
      <email>ayarkoray@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bursa Yüksek İhtisas Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Koray Ayar</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

